Aim Immunotech Stock Today
| AIM Stock | USD 0.22 0.01 4.29% |
Performance0 of 100
| Odds Of DistressOver 86
|
AIM ImmunoTech is selling at 0.219 as of the 12th of December 2024; that is 4.29 percent increase since the beginning of the trading day. The stock's lowest day price was 0.21. AIM ImmunoTech has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 12th of November 2024 and ending today, the 12th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of July 1996 | Category Healthcare | Classification Health Care |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. The company has 63.71 M outstanding shares of which 491.37 K shares are presently shorted by investors with about 1.63 days to cover. More on AIM ImmunoTech
Moving together with AIM Stock
Moving against AIM Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
AIM Stock Highlights
| Chairman | Thomas Equels | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAIM ImmunoTech can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AIM ImmunoTech's financial leverage. It provides some insight into what part of AIM ImmunoTech's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AIM ImmunoTech (AIM) is traded on NYSE MKT Exchange in USA. It is located in 2117 SW Highway 484, Ocala, FL, United States, 34473 and employs 26 people. AIM ImmunoTech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 13.41 M. AIM ImmunoTech runs under Biotechnology sector within Health Care industry. The entity has 63.71 M outstanding shares of which 491.37 K shares are presently shorted by investors with about 1.63 days to cover.
AIM ImmunoTech has about 27.05 M in cash with (21.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check AIM ImmunoTech Probability Of Bankruptcy
Ownership AllocationAIM ImmunoTech holds a total of 63.71 Million outstanding shares. AIM ImmunoTech shows 8.57 percent of its outstanding shares held by insiders and 14.07 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check AIM Ownership Details
AIM ImmunoTech Historical Income Statement
AIM Stock Against Markets
AIM ImmunoTech Corporate Management
| Wayne Springate | Senior Vice President - Operations | Profile | |
| III Esq | Exec COO | Profile | |
| Ann Coverly | Director Coordinator | Profile | |
| MBA IV | Chief Officer | Profile | |
| Stewart Appelrouth | Director | Profile |
Already Invested in AIM ImmunoTech?
The danger of trading AIM ImmunoTech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AIM ImmunoTech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AIM ImmunoTech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AIM ImmunoTech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.